Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash from Operations (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Cash from Operations for 15 consecutive years, with 388400000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 60.16% year-over-year to 388400000.0, compared with a TTM value of 782700000.0 through Dec 2025, up 31.46%, and an annual FY2025 reading of 782700000.0, up 31.46% over the prior year.
  • Cash from Operations was 388400000.0 for Q4 2025 at Neurocrine Biosciences, up from 227500000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 388400000.0 in Q4 2025 and bottomed at 125200000.0 in Q1 2023.
  • Average Cash from Operations over 4 years is 142715384.62, with a median of 130300000.0 recorded in 2024.
  • Peak annual rise in Cash from Operations hit 204.07% in 2024, while the deepest fall reached 64.03% in 2024.
  • Year by year, Cash from Operations stood at 87300000.0 in 2021, then soared by 41.47% to 123500000.0 in 2023, then surged by 96.36% to 242500000.0 in 2024, then soared by 60.16% to 388400000.0 in 2025.
  • Business Quant data shows Cash from Operations for NBIX at 388400000.0 in Q4 2025, 227500000.0 in Q3 2025, and 102000000.0 in Q2 2025.